:  

SPEAKERS

CAR-T vs. BiSpecifics: Brandy Anders, PharmD, BCOP

Clinical Controversies in Hematology and Oncology: Kevin Chen, PharmD, BCOP

Dr. Chen is a board certified clinical pharmacist practitioner at University of North Carolina Medical Center specializing in thoracic oncology & sarcoma. He is originally from Ohio and attended University of Kentucky College of Pharmacy where he completed both his graduate and pharmacy training. Subsequently, Kevin completed his PGY1 Pharmacy & PGY2 Oncology residency training at University of North Carolina Medical Center before starting his current role in the outpatient clinic. In his free time, he enjoys traveling, trying new breweries and restaurants, and cycling.

Precision Medicine in Oncology: Amber Cipriani, PharmD, BCOP

Amber Cipriani is a clinical pharmacist specialized in oncology care and pharmacogenomics. She currently serves as the Precision Medicine Pharmacy Coordinator at the University of North Carolina Medical Center where she works to implement initiatives that improve medication use and management through the utilization of technology, genetics, and clinical decision support tools. She is a member of the Molecular Tumor Board and Precision Oncology Program. She serves as the leader of the Pharmacogenomics Initiative of the Program for Precision Medicine in Health Care (PPMH) at UNC. Dr. Cipriani’s position is a joint funded position with the UNC Eshelman School of Pharmacy, where she serves as a Clinical Assistant Professor coordinates elective courses in pharmacogenomics and hematology/oncology pharmacotherapy for professional PharmD students.

CAR-T vs. BiSpecifics: Leah Edenfield, PharmD, BCOP

Leah Edenfield is an oncology clinical pharmacist at Atrium Health Wake Forest Baptist in Winston­Salem, NC. She specializes in lymphoma in the outpatient clinic setting and also works with adult inpatient oncology services. Leah is a clinical pharmacist practitioner with the stem cell transplant and cellular therapy team. She graduated from the UNC Eshelman School of Pharmacy and then completed her PGYl residency at Sentara RMH Medical Center in Harrisonburg, VA and PGY2 oncology residency at Virginia Commonwealth University Health System in Richmond, VA. Leah is originally from Virginia Beach and enjoys traveling to the beach often.

Keynote: Jason Kotecki

New Drug Update: Jordyn Higgins, PharmD, BCOP

Dr. Higgins is a Thoracic/Head & Neck Clinical Oncology Pharmacist at Duke Cancer Institute. She graduated from the UNC Eshelman School of Pharmacy with honors and distinction. Afterwards, she completed her PGY-1 pharmacy practice and PGY-2 oncology pharmacy residencies at Emory University Hospital Midtown/Emory Winship Cancer Institute. Prior to her current role she practiced as an Oncology Clinical Pharmacy Specialist at Emory Winship Cancer Institute. She is actively involved in national pharmacy organizations and has served as the Chair for the ASHP New Practitioners Forum Clinical Practice Advisory Group and Chair for the HOPA Student Advisory Group. She is passionate about advancing the role of pharmacists in oncology care and improving the outcomes and quality of life of cancer patients.

CLL: Chris Parish, PharmD

Chris Parish is originally from Tampa, Florida. After attending Rhodes College for his undergraduate education, he attended the University of North Carolina Eshelman School of Pharmacy in Chapel Hill, North Carolina. He then completed PGY1 Pharmacy and PGY2 Oncology residencies at Atrium Health Wake Forest Baptist Medical Center in Winston Salem, North Carolina. After residency, he will be staying on Wake Forest Baptist as the classical hematology and blood factor stewardship pharmacist. In his free time, Chris enjoys reading, spending time with friends at breweries, and going on walks with Max the mini Bernie-Doodle.

Clinical Controversies in Hematology and Oncology: Daniel Schrum, PharmD, BCOP

Daniel Schrum is originally from Pittsburgh, PA. He received his Bachelor of Science and Doctor of Pharmacy Degrees from the University of Pittsburgh. He completed his PGY1 acute care residency and PGY2 oncology residency at Duke University Hospital where he is now inpatient cellular therapies lead within the malignant hematology group. His practice interests include novel cellular therapies and infectious disease in immunocompromised populations. In addition to his clinical responsibilities, Dr. Schrum serves on the CAR T Committee and is involved in ongoing clinical research related to improvement of safety and outcomes in patients receiving cellular therapies.

Cardiotoxicity: Taylor Thompson, PharmD

Updates in Bladder Cancer: Kallie White, PharmD, BCOP